Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:

H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 10, 202412:30 p.m. ET – fireside chat

A simultaneous webcast of each event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.

About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.

Nkarta Media/Investor Contact:Greg MannNkarta, Inc.gmann@nkartatx.com

Nkarta (NASDAQ:NKTX)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Nkarta Charts.
Nkarta (NASDAQ:NKTX)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Nkarta Charts.